Fully Automated Diagnosis and Prognostic Testing for RA

NICE guidelines now recommend testing for anti-CCP, a highly specific marker for rheumatoid arthritis (RA), in the management of patients with suspected RA where tests for rheumatoid factor (RF) are negative.

The Elecsys nti-CCP assay from Roche is one of the first fully automated, second generation tests for the determination of human IgG autoantibodies to cyclic citrullinated peptides (anti-CCP) in serum or plasma. Unlike other RA markers, such as RF and c-reactive protein (CRP), anti-CCP is the only highly specific assay for RA and can predict the eventual development of RA when found in undifferentiated arthritis. The Elecsys Anti-CCP assay provides excellent precision2 from a small sample volume (15μl), ensuring reliable results in just 18 minutes.

The Elecsys Anti-CCP assay is a valuable diagnostic and prognostic marker for RA and is available on the Roche MODULAR Analytics, cobas 6000 and cobas 4000 systems. Clinical laboratories can therefore consolidate testing for different autoimmune tests (anti-CCP, anti-TG, anti-TSHR and anti-TPO), RF and CRP on a single serum work area (SWA) platform.